© Reuters. FILE PHOTO: Syringes with needles are seen in front of a displayed Moderna logo in this illustration taken November 27, 2021. REUTERS/Dado Ruvic/Illustration
TOKYO (Reuters) – Moderna (NASDAQ:) Inc believed from the beginning of the COVID-19 pandemic that BioNTech SE (NASDAQ:) used its intellectual property in producing a rival vaccine, Chief Executive Stephane Bancel said on Wednesday.
Moderna filed suit against BioNTech and its partner Pfizer Inc (NYSE:) last month for patent infringement in the development of the first COVID-19 vaccine approved in the United States.
Bancel, speaking in Tokyo, said Moderna is considering building facilities in Japan to produce mRNA-derived products.